- Home
- CLLS vs GLO Comparison
CLLS vs GLO Comparison
Compare CLLS & GLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- GLO
- Stock Information
- Founded
- CLLS 1999
- GLO 2006
- Country
- CLLS France
- GLO United States
- Employees
- CLLS N/A
- GLO N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- GLO Finance/Investors Services
- Sector
- CLLS Health Care
- GLO Finance
- Exchange
- CLLS Nasdaq
- GLO Nasdaq
- Market Cap
- CLLS 143.4M
- GLO 193.7M
- IPO Year
- CLLS 2007
- GLO N/A
- Fundamental
- Price
- CLLS $1.58
- GLO $5.50
- Analyst Decision
- CLLS Buy
- GLO
- Analyst Count
- CLLS 1
- GLO 0
- Target Price
- CLLS $4.00
- GLO N/A
- AVG Volume (30 Days)
- CLLS 54.7K
- GLO 170.5K
- Earning Date
- CLLS 08-05-2025
- GLO 01-01-0001
- Dividend Yield
- CLLS N/A
- GLO 11.38%
- EPS Growth
- CLLS N/A
- GLO N/A
- EPS
- CLLS N/A
- GLO N/A
- Revenue
- CLLS $54,747,000.00
- GLO N/A
- Revenue This Year
- CLLS $48.52
- GLO N/A
- Revenue Next Year
- CLLS $5.17
- GLO N/A
- P/E Ratio
- CLLS N/A
- GLO N/A
- Revenue Growth
- CLLS 351.26
- GLO N/A
- 52 Week Low
- CLLS $1.10
- GLO $4.08
- 52 Week High
- CLLS $2.43
- GLO $5.18
- Technical
- Relative Strength Index (RSI)
- CLLS 64.58
- GLO 67.58
- Support Level
- CLLS $1.41
- GLO $5.31
- Resistance Level
- CLLS $1.65
- GLO $5.32
- Average True Range (ATR)
- CLLS 0.10
- GLO 0.05
- MACD
- CLLS 0.03
- GLO 0.01
- Stochastic Oscillator
- CLLS 93.81
- GLO 88.46
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.